----------------------------------------------
------------------------------------------------------------------
Glioblastoma, as well as other conditions, can be targeted by drugs but what exactly does this entail? I think that there are many aspects to take into account and therapies are only going to be able to make the most out of these components if they are approved. Once this is done, researchers will be able to implement them during certain parts of procedures, whether they come before or after surgery. That being said, what is the story behind a particular drug that has been named VB-111?
An article on Pharmaceutical Business Review spoke about VB-111 and there is quite a bit to go over in this regard. Recently, the drug was responsible for VBL Therapeutics being given fast track status from the US Food and Drug Administration. What this particular drug is able to do, in theory, is extend survival rates in patients with glioblastoma. When considering the potential impact that VB-111 can have, it's no wonder as to why this particular status was given. There is more to consider, though, as organizations like Voices against Brain Cancer can tell you.
I think that there will be those who will agree that this drug has garnered attention in the past. VB-111, early on, was granted orphan drug status, so it isn't like this has gone under the radar by any means. In theory, this means that the drug in question can be used for the sake of aiding those with glioblastoma, which has a poor prognosis already. This means that there will always be efforts put forth in order to make sure that these particular tumors are taken care of.
The way that this particular drug works is that it is given as an IV fusion, which is where it will be able to target the impacted areas of the body. More specifically, it is able to take care of endothelial cells in the tumor, working as a biological knife, according to the report. One of the positive points to consider about this drug is that it is able to target the impacted areas alone, meaning that noncancerous tissue will be left unharmed. In the medical field, I cannot imagine many points that are as vital.
This particular condition is going to call for a number of procedures, so it's fair to assume that certain drugs will be put to use more than others. VB-111, in my opinion, is unique in that it is able to promote safety in patients following usage. I do not think that anyone can argue with this point, especially when the findings have shown this. I have to believe that this will be able to help others in the long term, so make sure that this is kept in mind.
An article on Pharmaceutical Business Review spoke about VB-111 and there is quite a bit to go over in this regard. Recently, the drug was responsible for VBL Therapeutics being given fast track status from the US Food and Drug Administration. What this particular drug is able to do, in theory, is extend survival rates in patients with glioblastoma. When considering the potential impact that VB-111 can have, it's no wonder as to why this particular status was given. There is more to consider, though, as organizations like Voices against Brain Cancer can tell you.
I think that there will be those who will agree that this drug has garnered attention in the past. VB-111, early on, was granted orphan drug status, so it isn't like this has gone under the radar by any means. In theory, this means that the drug in question can be used for the sake of aiding those with glioblastoma, which has a poor prognosis already. This means that there will always be efforts put forth in order to make sure that these particular tumors are taken care of.
The way that this particular drug works is that it is given as an IV fusion, which is where it will be able to target the impacted areas of the body. More specifically, it is able to take care of endothelial cells in the tumor, working as a biological knife, according to the report. One of the positive points to consider about this drug is that it is able to target the impacted areas alone, meaning that noncancerous tissue will be left unharmed. In the medical field, I cannot imagine many points that are as vital.
This particular condition is going to call for a number of procedures, so it's fair to assume that certain drugs will be put to use more than others. VB-111, in my opinion, is unique in that it is able to promote safety in patients following usage. I do not think that anyone can argue with this point, especially when the findings have shown this. I have to believe that this will be able to help others in the long term, so make sure that this is kept in mind.
About the Author:
Visit Voices Against Brain Cancer if you are seeking some additional information about brain cancer awareness.. Also published at Glioblastoma & The Potential Usage Of VB-111.
0 comments:
Post a Comment